Berdazimer sodium
Zelsuvmi (berdazimer sodium) is a small molecule pharmaceutical. Berdazimer sodium was first approved as Zelsuvmi on 2024-01-05.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
BERDAZIMER SODIUM, ZELSUVMI, LNHC | |||
| 2029-01-05 | NCE | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Berdazimer Sodium, Zelsuvmi, Lnhc | |||
| 10322081 | 2035-07-10 | U-3793, U-3794, U-3795, U-3796 | |
| 10736839 | 2035-07-10 | U-3790, U-3791, U-3792 | |
| 11040006 | 2035-07-10 | DP | U-3789 |
| 11723858 | 2035-07-10 | DP | U-3788 |
| 10258564 | 2034-11-22 | U-3797, U-3798, U-3799 | |
| 11285098 | 2034-02-28 | DP | |
| 9855211 | 2034-02-27 | DP | U-3800, U-3801 |
| 9289442 | 2032-07-03 | DP | U-3803 |
| 10265334 | 2032-07-03 | DP | |
| 9526738 | 2031-09-03 | DP | |
| 9737561 | 2030-08-20 | U-3802 | |
| 10376538 | 2030-08-20 | DP | |
| 8282967 | 2026-05-30 | DP | |
| 8956658 | 2026-05-30 | DP | |
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
21 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acne vulgaris | D000152 | EFO_0003894 | L70 | 8 | 3 | 3 | — | — | 13 |
| Molluscum contagiosum | D008976 | EFO_0007375 | B08.1 | — | 1 | 3 | — | — | 4 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Tinea | D014005 | EFO_0007510 | B35.9 | — | 1 | — | — | — | 1 |
| Tinea pedis | D014008 | EFO_0007512 | B35.3 | — | 1 | — | — | — | 1 |
| Warts | D014860 | — | B07 | — | 1 | — | — | — | 1 |
| Condylomata acuminata | D003218 | EFO_0007147 | A63.0 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Psoriasis | D011565 | EFO_0000676 | L40 | 1 | — | — | — | — | 1 |
| Atopic dermatitis | D003876 | EFO_0000274 | L20 | 1 | — | — | — | — | 1 |
| Eczema | D004485 | HP_0000964 | L30.9 | 1 | — | — | — | — | 1 |
| Dermatitis | D003872 | HP_0011123 | L30.9 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Berdazimer sodium |
| INN | berdazimer sodium |
| Description | Berdazimer sodium, sold under the brand name Zelsuvmi, is a medication used for the treatment for molluscum contagiosum. Berdazimer sodium is a nitric oxide releasing agent. It is a polymer formed from sodium 1-hydroxy-3-methyl-3-(3-(trimethoxysilyl)propyl)-1-triazene-2-oxide and tetraethyl silicate.
|
| Classification | Small molecule |
| Drug class | polymers |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL4298064 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DBSALT003491 |
| UNII ID | ORT9SID4QY (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 55 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use